| Original language | English |
|---|---|
| Pages (from-to) | 1723-1727 |
| Number of pages | 5 |
| Journal | Leukemia and Lymphoma |
| Volume | 63 |
| Issue number | 7 |
| DOIs | |
| State | Published - 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Leukemia and Lymphoma, Vol. 63, No. 7, 2022, p. 1723-1727.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL
T2 - single institution experience
AU - Mehta-Shah, Neha
AU - Bartlett, Nancy L.
AU - Kahl, Brad
AU - Watkins, Marcus P.
AU - Dubois, Amalia
AU - Schmelzle, Gabby
AU - Waqar, Saiama
AU - Ballman, Claire
AU - Wan, Fei
AU - Farnsworth, Christopher W.
N1 - Funding Information: N.M-S has research funding from Bristol Myers-Squibb, Astrazeneca Pharmaceuticals, Celgene, Secura Bio, Verastem, Roche/Genentech, C4 Therapeutics, Corvus, Innate Pharmaceuticals, Daiichi Sankyo. N. M-S has consulted for Secura Bio, Daiichi sankyo, C4 Therapeutics, Karyopharm Therapeutics, Kyowa Hakka Kirin. N.L.B has research funding from ADC Therapeutics, Affimed, Autolus, Bristol-Myers Squibb, Celgene, Forty Seven, Immune Design, Janssen, Kite Pharma/Gilead, Merck, Millennium, Pharmacyclics, Pfizer, Roche/Genentech, and SeaGen, and been on advisory boards for Acerta, ADC Therapeutics, BTG, Roche/Genentech, and SeaGen. B.K has research funding from AcertaPharma/AstraZeneca Group, Astrazeneca Pharmaceuticals LP, BeiGene Ltd., Roche/Genetech, has been on advisory boards for Abbvie, ADC Therapeutics, Astrazeneca Pharmaceuticals LP, Beigne Ltd., Celgene Corporations, Epizyme Inc., Roche/Genetech, Pharmacyclics, LLC an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc and has served on the data & safety monitoring board/committee for Celgene Corporations, MEI Pharma Inc., Takeda Oncology. C.W.F has research funding from Abbott Laboratories, Roche Diagnostics, Beckman Coulter, The Binding Site, Siemens Healthineers, has consulted for Roche Diagnostics and has had speaking fees from Roche Diagnostics. S.W. has research funding from AbbVie Inc, Ariad Pharmaceuticals, Genentech, Immunomedics, Inc., Millennium Pharmaceuticals Inc, Roche, Astellas Pharma Inc, Daiichi Sankyo, Cullinan Pearl, Verastem Inc, GlaxoSmithKline/GSK, Janssen Research & Development, LLC, Elevation Oncology, Daiichi Sankyo, Genentech, Loxo Oncology, Takeda Pharmaceuticals Company Limited. S.W. serves on the stat safety monitoring board for Hooiser Cancer Research Network. M.P.W, A.D, C.B., G.S and F.W have no conflicts of interest. Funding Information: The authors would like to thank the Barnes-Jewish Hospital Foundation for support. N. M-S is supported by the Lymphoma Research Foundation. The authors are indebted to the nursing and research staff involved in these studies and to all the participants and their families.
PY - 2022
Y1 - 2022
UR - https://www.scopus.com/pages/publications/85125918784
U2 - 10.1080/10428194.2022.2038377
DO - 10.1080/10428194.2022.2038377
M3 - Letter
C2 - 35225130
AN - SCOPUS:85125918784
SN - 1042-8194
VL - 63
SP - 1723
EP - 1727
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 7
ER -